Lev Facher

Washington Correspondent

Lev Facher is a Washington Correspondent for STAT, reporting on the politics of health and life sciences. He has written extensively about the federal government's response to the opioid crisis, the pharmaceutical industry's influence on Capitol Hill, and federally funded biomedical research. Lev earned an economics degree from the University of Michigan, where he worked as managing editor of The Michigan Daily. You can reach him via email at lev.facher@statnews.com and by phone/WhatsApp/Signal at (510)-374-8880.

In the Lab

Lev Facher

Washington Correspondent

Beyond the pale (ale): FDA orders pharma lab to can its microbrewery operation

AMA urges Congress not to loosen restrictions on privacy for patients with addiction history

GOP lawmakers seeking to use opioids bill to deliver drug industry major victory

In unlikely alliance, PhRMA sides with landlords in Calif. referendum on rent control

What’s in, what’s out, and what’s still on the table in the opioids package passed by the Senate

A different kind of house call: Teams bring addiction care to patients, wherever they are

Is mistrust of ‘big pharma’ enough to help unseat a Democratic stalwart in Congress?

A drug distributor flagged a pharmacy’s suspicious opioid orders. A federal court says it has to keep shipping the pills

The Senate could soon pass an opioids package. But a new law is still a long way away

Sacha Baron Cohen tried to prank Francis Collins. He got a science lesson instead

NIH is investigating researchers who might have failed to disclose contributions from foreign governments

Tapered to zero: In radical move, Oregon’s Medicaid program weighs cutting off chronic pain patients from opioids

Trump’s new tone with drug makers: gratitude

Drug pricing could be a slam-dunk campaign issue for Democrats — if only they had a plan

FDA will broaden how it evaluates new addiction treatment drugs

Series of ethical stumbles tests NIH’s reliance on private sector for research funding

Democrats take aim at high drug prices with bill allowing Medicare to negotiate

With latest defeat in South Dakota, drug pricing initiatives unlikely to see the ballot in 2018

Lev Facher

Washington Correspondent

Sign up for our Morning Rounds newsletter